Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression

T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these ke...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 16; p. 1662145
Main Authors: Li, Guangmei, Li, Dengju, Zhu, Xiaojian
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 2025
Subjects:
Animals
Cellular Senescence - immunology
Humans
Immunotherapy - methods
Immunotherapy, Adoptive - methods
Lymphocyte Activation
metabolic regulation
microenvironment optimization
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - therapy
T-cell enhancement
T-cell exhaustion and aging
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
T-Lymphocytes - transplantation
tumor immunotherapy
Tumor Microenvironment - immunology
tumor immunotherapy
T-cell enhancement
T-cell exhaustion and aging
metabolic regulation
microenvironment optimization
ISSN:1664-3224, 1664-3224
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these key issues and proposed targeted improvement strategies. Emerging approaches encompass pharmacological modulation of T cell activation and survival pathways, epigenetic reprogramming to reverse exhaustion and senescence, metabolic engineering, combinatorial targeting of immunosuppressive TME components and advanced genetic tools, notably CRISPR-Cas9–based CAR-T optimization, which exemplifies how precise genome editing can enhance therapeutic efficacy. We review the progress and prospects of T-cell improvement strategies in tumor immunotherapy, emphasizing the need for further exploration to enhance the broader application and long-term efficacy of T-cell therapies. This review highlights recent advances and future directions in T-cell engineering, metabolic modulation, and microenvironment targeting, aiming to translate innovations into effective cancer immunotherapies.
AbstractList T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these key issues and proposed targeted improvement strategies. Emerging approaches encompass pharmacological modulation of T cell activation and survival pathways, epigenetic reprogramming to reverse exhaustion and senescence, metabolic engineering, combinatorial targeting of immunosuppressive TME components and advanced genetic tools, notably CRISPR-Cas9-based CAR-T optimization, which exemplifies how precise genome editing can enhance therapeutic efficacy. We review the progress and prospects of T-cell improvement strategies in tumor immunotherapy, emphasizing the need for further exploration to enhance the broader application and long-term efficacy of T-cell therapies. This review highlights recent advances and future directions in T-cell engineering, metabolic modulation, and microenvironment targeting, aiming to translate innovations into effective cancer immunotherapies.
T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these key issues and proposed targeted improvement strategies. Emerging approaches encompass pharmacological modulation of T cell activation and survival pathways, epigenetic reprogramming to reverse exhaustion and senescence, metabolic engineering, combinatorial targeting of immunosuppressive TME components and advanced genetic tools, notably CRISPR-Cas9-based CAR-T optimization, which exemplifies how precise genome editing can enhance therapeutic efficacy. We review the progress and prospects of T-cell improvement strategies in tumor immunotherapy, emphasizing the need for further exploration to enhance the broader application and long-term efficacy of T-cell therapies. This review highlights recent advances and future directions in T-cell engineering, metabolic modulation, and microenvironment targeting, aiming to translate innovations into effective cancer immunotherapies.T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these key issues and proposed targeted improvement strategies. Emerging approaches encompass pharmacological modulation of T cell activation and survival pathways, epigenetic reprogramming to reverse exhaustion and senescence, metabolic engineering, combinatorial targeting of immunosuppressive TME components and advanced genetic tools, notably CRISPR-Cas9-based CAR-T optimization, which exemplifies how precise genome editing can enhance therapeutic efficacy. We review the progress and prospects of T-cell improvement strategies in tumor immunotherapy, emphasizing the need for further exploration to enhance the broader application and long-term efficacy of T-cell therapies. This review highlights recent advances and future directions in T-cell engineering, metabolic modulation, and microenvironment targeting, aiming to translate innovations into effective cancer immunotherapies.
Author Li, Dengju
Li, Guangmei
Zhu, Xiaojian
Author_xml – sequence: 1
  givenname: Guangmei
  surname: Li
  fullname: Li, Guangmei
– sequence: 2
  givenname: Dengju
  surname: Li
  fullname: Li, Dengju
– sequence: 3
  givenname: Xiaojian
  surname: Zhu
  fullname: Zhu, Xiaojian
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41159033$$D View this record in MEDLINE/PubMed
BookMark eNpNkctOwzAQRS1UBAX6AyxQlixI8TsJO1TxkhBsisTOcpxJG9TYwU4Q_D0OLQhvPBof37HvPUIT6ywgdErwnLG8uKybth3mFFMxJ1JSwsUemsaKp4xSPvlXH6JZCG84Ll4wxsQBOuSEiAIzNkWvT_DZpyuw4HXfOJssEwObTTKqW9evY7v7ukrcB3jj2sauEvhc6yGM7EUS4r1gwBq4SLStkjB0nYcQ4uEJ2q_1JsBstx-jl9ub5eI-fXy-e1hcP6aGSdmnYLCsWJlnueHxxUUli1qXhSgp57koJBQZrXhFSEZLDEKynNI6jx8WGcFMUnaMHra6ldNvqvNNq_2XcrpRPw3nV0r7vjEbUIJqoSXRUbbmoHkpq1xiWQJgTYHzqHW-1eq8ex8g9KptwmiHtuCGoBiNnooMSxbRsx06lC1Uf4N_nY0A3QLGuxA81H8IwWpMUP0kqMYE1S5B9g2Q_Y3K
Cites_doi 10.1016/j.cell.2016.05.035
10.1038/s41423-019-0344-8
10.1038/s41586-020-2682-1
10.1038/s41596-019-0249-0
10.3389/fendo.2020.624122
10.1158/1078-0432.CCR-19-2625
10.4161/onci.27573
10.1038/mt.2015.77
10.1038/s41467-017-02358-7
10.1186/s13045-020-00986-z
10.4110/in.2019.19.e11
10.4049/jimmunol.1701703
10.1182/blood-2014-07-589176
10.1038/s41467-020-19672-2
10.1186/s13045-023-01504-7
10.1158/1078-0432.CCR-22-3642
10.1016/j.clim.2025.110486
10.1038/nm.1982
10.1016/j.ccell.2017.08.004
10.1172/jci.insight.137263
10.1038/nature12951
10.1016/j.immuni.2016.07.009
10.1038/s41419-023-05937-3
10.3389/fbioe.2023.1248421
10.1007/s40778-016-0040-x
10.1002/art.41420
10.1172/jci.insight.93411
10.1126/science.1229620
10.1038/s41571-025-01061-7
10.1126/science.aaf6284
10.1016/j.bbmt.2015.05.022
10.1158/2326-6066.CIR-18-0095
10.1186/s13045-016-0388-5
10.1038/nm.4241
10.1136/jitc-2021-003958
10.1038/s43587-023-00416-y
10.1016/j.ctrv.2017.10.002
10.1038/nature19317
10.3389/fimmu.2024.1426620
10.1016/j.bbrc.2017.12.041
10.1186/s13148-024-01740-9
10.1016/j.immuni.2016.07.021
10.1126/scitranslmed.3007974
10.1038/ni.2035
10.1146/annurev-med-062518-045435
10.1056/NEJMoa1003466
10.3389/fimmu.2025.1615611
10.1038/s41577-019-0140-9
10.1038/s41568-019-0109-9
10.1126/sciimmunol.adn6509
10.1038/nri3740
10.1172/jci.insight.96976
10.1016/j.smim.2015.10.007
10.1038/s41556-022-00991-z
10.1038/s41590-024-02062-x
10.1083/jcb.201710132
10.1007/s11912-024-01544-3
10.1016/j.ccell.2021.04.004
10.1002/art.38261
10.3350/cmh.2024.0465
10.1186/s12943-020-01234-1
10.1182/blood-2015-06-649145
10.1084/jem.20061104
10.1038/s41586-018-0178-z
10.1182/blood-2012-05-431718
10.1158/1078-0432.CCR-18-1231
10.1016/j.jcyt.2017.03.067
10.1038/s41590-025-02134-6
10.1111/j.1600-065X.2012.01150.x
10.1038/s41467-023-42634-3
10.1126/science.aaa6204
10.1016/j.it.2014.02.003
10.1016/j.jhep.2018.10.040
10.1172/JCI80005
10.1186/s13045-017-0478-z
10.1126/science.adl4492
10.1158/2159-8290.CD-18-0367
10.3390/ijms22031074
10.1016/j.immuni.2018.12.021
10.1128/MCB.25.21.9543-9553.2005
10.1007/s13238-019-0643-y
10.1136/jitc-2020-001536
10.1016/j.stem.2012.11.002
10.1016/j.ccell.2015.09.004
10.1038/s41586-020-2403-9
10.1158/1078-0432.CCR-20-0113
10.1186/s12935-021-02407-8
10.1186/s40364-024-00602-z
10.1158/2767-9764.CRC-22-0090
10.1016/j.cell.2017.02.031
10.1158/1078-0432.CCR-14-0830
10.1016/j.bbmt.2014.03.007
10.1186/s13045-020-0843-1
10.1186/s13045-018-0629-x
10.1016/j.it.2015.02.008
10.1186/s13045-022-01242-2
10.1038/s41586-019-1821-z
10.1158/2159-8290.CD-21-0764
10.3389/fimmu.2022.990463
10.1158/2326-6066.CIR-19-0115
10.1016/j.bbmt.2017.05.032
10.1172/JCI69589
10.1016/j.tibtech.2024.08.004
10.1126/scitranslmed.3009892
10.1111/cts.13387
10.1056/NEJMoa2300503
10.1158/2326-6066.CIR-24-0110
10.1172/jci.insight.99048
10.1186/s40164-020-00190-2
10.1016/j.ccell.2016.04.014
10.3390/ijms232314563
10.1038/nature19330
10.1186/s13045-024-01563-4
10.1016/j.immuni.2025.02.009
ContentType Journal Article
Copyright Copyright © 2025 Li, Li and Zhu.
Copyright_xml – notice: Copyright © 2025 Li, Li and Zhu.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.3389/fimmu.2025.1662145
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_52a5a61a596f4ea4b6d8606bee0a2e44
41159033
10_3389_fimmu_2025_1662145
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
M48
NPM
RIG
7X8
ID FETCH-LOGICAL-c366t-ec06d3b878c41669d69fab95b2448596e972d4d1172b0e563822f866257103623
IEDL.DBID DOA
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001600214200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1664-3224
IngestDate Mon Oct 20 20:30:18 EDT 2025
Wed Oct 29 17:10:47 EDT 2025
Sat Nov 01 14:17:37 EDT 2025
Thu Oct 16 04:36:19 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords tumor immunotherapy
T-cell enhancement
T-cell exhaustion and aging
metabolic regulation
microenvironment optimization
Language English
License Copyright © 2025 Li, Li and Zhu.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c366t-ec06d3b878c41669d69fab95b2448596e972d4d1172b0e563822f866257103623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://doaj.org/article/52a5a61a596f4ea4b6d8606bee0a2e44
PMID 41159033
PQID 3266457063
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_52a5a61a596f4ea4b6d8606bee0a2e44
proquest_miscellaneous_3266457063
pubmed_primary_41159033
crossref_primary_10_3389_fimmu_2025_1662145
PublicationCentury 2000
PublicationDate 2025-00-00
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – year: 2025
  text: 2025-00-00
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2025
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Jang (B114) 2023; 29
Teijeira (B34) 2019; 7
Zhang (B18) 2025; 275
Grover (B94) 2021; 11
Kasakovski (B67) 2018; 11
Tuckett (B68) 2017; 10
Yu (B99) 2019; 70
Wherry (B9) 2011; 12
Zhao (B37) 2015; 28
Pauken (B10) 2015; 36
Sui (B100) 2022; 13
León MaChado (B6) 2021; 22
Reck (B88) 2025
Hodi (B1) 2010; 363
Liu (B36) 2020; 11
Chen (B92) 2025; 26
Utzschneider (B25) 2016; 45
Zheng (B107) 2023; 11
Zhang (B84) 2017; 32
Constantin (B26) 2024; 12
Xu (B38) 2025; 16
Brunschwiler (B4) 2024; 15
Son (B75) 2019; 19
Lee (B5) 2024; 30
Politikos (B65) 2014; 124
Speiser (B24) 2014; 14
Gao (B53) 2021; 9
Lanna (B46) 2022; 24
Bian (B111) 2020; 585
Jarjour (B19) 2025; 58
Lian (B44) 2020; 13
Nishimura (B51) 2013; 12
Gattinoni (B54) 2009; 15
Steeghs (B106) 2022; 15
Marvel (B101) 2015; 125
Choudhuri (B45) 2014; 507
Fan (B69) 2015; 23
Huffman (B102) 2020; 5
Zhang (B27) 2020; 15
Highfill (B96) 2014; 6
Tajima (B70) 2016; 2
Wu (B85) 2022; 15
Rizk (B66) 2017; 23
Peng (B12) 2016; 354
Andtbacka (B16) 2022; 2
DeBoy (B48) 2023; 388
Sukumar (B73) 2014; 3
Sukumar (B74) 2013; 123
Chellappa (B89) 2019; 202
Farge (B62) 2017; 10
Li (B90) 2020; 19
He (B108) 2016; 537
Baar (B58) 2017; 169
Mannick (B55) 2014; 6
Greene (B95) 2020; 26
Hornburg (B15) 2021; 39
Kang (B20) 2024; 386
Rueff (B63) 2014; 20
Wei (B83) 2019; 576
Amor (B59) 2020; 583
van der Windt (B79) 2012; 249
O'Sullivan (B71) 2019; 19
Odagiu (B32) 2020; 11
Scharping (B82) 2016; 45
Patel (B113) 2024; 9
Cao (B77) 2023; 14
Yang (B17) 2020; 13
Dotsu (B72) 2022; 10
Im (B23) 2016; 537
Guedan (B30) 2018; 3
Wang (B35) 2018; 3
Buck (B80) 2016; 166
Kaartinen (B42) 2017; 19
Ni (B91) 2015; 21
Serafini (B98) 2006; 203
Peters (B110) 2018; 62
Chowdhury (B81) 2018; 6
Vafaei (B86) 2022; 22
Bulliard (B33) 2023; 16
Wang (B103) 2020; 26
Wei (B3) 2018; 8
Siddiqui (B31) 2019; 50
Cieri (B39) 2013; 121
Zhang (B43) 2018; 495
Song (B52) 2024; 12
Song (B56) 2024; 17
Joyce (B13) 2015; 348
Gattinoni (B22) 2017; 23
Dang (B104) 2024; 16
Bertrand (B87) 2017; 8
Mannick (B57) 2023; 3
Wu (B21) 2023; 14
Delemarre (B61) 2016; 127
Parry (B8) 2005; 25
Steele (B97) 2016; 29
Teppert (B7) 2022; 23
Paley (B109) 2012; 338
Karagiannis (B50) 2016; 28
Zhou (B41) 2019; 10
Crompton (B49) 2014; 35
McCarthy (B2) 2006; 26
Souto-Carneiro (B76) 2020; 72
Zhao (B11) 2020; 17
Wang (B28) 2024; 26
Siquenique (B29) 2025; 43
Zhang (B40) 2020; 9
Jones (B115) 2019; 19
Tallón de Lara (B93) 2018; 24
Fraietta (B112) 2018; 558
Vonderheide (B105) 2020; 71
Damien (B64) 2015; 21
Delemarre (B60) 2014; 66
Messenger (B47) 2018; 217
Siska (B78) 2017; 2
Shakiba (B14) 2025; 26
References_xml – volume: 166
  start-page: 63
  year: 2016
  ident: B80
  article-title: Mitochondrial dynamics controls T cell fate through metabolic programming
  publication-title: Cell
  doi: 10.1016/j.cell.2016.05.035
– volume: 17
  start-page: 27
  year: 2020
  ident: B11
  article-title: Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-019-0344-8
– volume: 585
  year: 2020
  ident: B111
  article-title: Cancer SLC43A2 alters T cell methionine metabolism and histone methylation
  publication-title: Nature
  doi: 10.1038/s41586-020-2682-1
– volume: 15
  year: 2020
  ident: B27
  article-title: Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds
  publication-title: Nat Protoc
  doi: 10.1038/s41596-019-0249-0
– volume: 11
  year: 2020
  ident: B32
  article-title: Role of the orphan nuclear receptor NR4A family in T-cell biology
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2020.624122
– volume: 26
  year: 2020
  ident: B95
  article-title: Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-2625
– volume: 3
  year: 2014
  ident: B73
  article-title: The short and sweet of T-cell therapy: Restraining glycolysis enhances the formation of immunological memory and antitumor immune responses
  publication-title: Oncoimmunology
  doi: 10.4161/onci.27573
– volume: 23
  year: 2015
  ident: B69
  article-title: Bioengineering thymus organoids to restore thymic function and induce donor-specific immune tolerance to allografts
  publication-title: Mol Ther
  doi: 10.1038/mt.2015.77
– volume: 8
  start-page: 2256
  year: 2017
  ident: B87
  article-title: TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-02358-7
– volume: 13
  start-page: 151
  year: 2020
  ident: B44
  article-title: Immunosenescence: a key player in cancer development
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00986-z
– volume: 19
  start-page: e11
  year: 2019
  ident: B75
  article-title: Metabolic reprogramming by the excessive AMPK activation exacerbates antigen-specific memory CD8(+) T cell differentiation after acute lymphocytic choriomeningitis virus infection
  publication-title: Immune Netw
  doi: 10.4110/in.2019.19.e11
– volume: 202
  year: 2019
  ident: B89
  article-title: The PI3K p110δ Isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1701703
– volume: 124
  year: 2014
  ident: B65
  article-title: The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation
  publication-title: Blood
  doi: 10.1182/blood-2014-07-589176
– volume: 11
  start-page: 5902
  year: 2020
  ident: B36
  article-title: Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-19672-2
– volume: 16
  start-page: 108
  year: 2023
  ident: B33
  article-title: Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-023-01504-7
– volume: 29
  year: 2023
  ident: B114
  article-title: A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-22-3642
– volume: 275
  start-page: 110486
  year: 2025
  ident: B18
  article-title: T cell aging and exhaustion: Mechanisms and clinical implications
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2025.110486
– volume: 15
  year: 2009
  ident: B54
  article-title: Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
  publication-title: Nat Med
  doi: 10.1038/nm.1982
– volume: 32
  start-page: 377
  year: 2017
  ident: B84
  article-title: Enhancing CD8(+) T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.08.004
– volume: 5
  year: 2020
  ident: B102
  article-title: CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.137263
– volume: 507
  year: 2014
  ident: B45
  article-title: Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse
  publication-title: Nature
  doi: 10.1038/nature12951
– volume: 45
  year: 2016
  ident: B82
  article-title: The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.07.009
– volume: 14
  start-page: 407
  year: 2023
  ident: B77
  article-title: Effects of altered glycolysis levels on CD8(+) T cell activation and function
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-023-05937-3
– volume: 11
  year: 2023
  ident: B107
  article-title: Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms
  publication-title: Front Bioeng Biotechnol
  doi: 10.3389/fbioe.2023.1248421
– volume: 2
  year: 2016
  ident: B70
  article-title: Restoration of thymus function with bioengineered thymus organoids
  publication-title: Curr Stem Cell Rep
  doi: 10.1007/s40778-016-0040-x
– volume: 72
  year: 2020
  ident: B76
  article-title: Effect of increased lactate dehydrogenase A activity and aerobic glycolysis on the proinflammatory profile of autoimmune CD8+ T cells in rheumatoid arthritis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.41420
– volume: 2
  year: 2017
  ident: B78
  article-title: Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.93411
– volume: 338
  year: 2012
  ident: B109
  article-title: Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection
  publication-title: Science
  doi: 10.1126/science.1229620
– year: 2025
  ident: B88
  article-title: Treatment of NSCLC after chemoimmunotherapy - are we making headway
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-025-01061-7
– volume: 354
  year: 2016
  ident: B12
  article-title: Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism
  publication-title: Science
  doi: 10.1126/science.aaf6284
– volume: 21
  year: 2015
  ident: B64
  article-title: Regenerative therapy and immune modulation using umbilical cord blood-derived cells
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2015.05.022
– volume: 6
  year: 2018
  ident: B81
  article-title: PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8(+) T cells and facilitates anti-PD-1 therapy
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-18-0095
– volume: 10
  start-page: 21
  year: 2017
  ident: B62
  article-title: Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-016-0388-5
– volume: 23
  start-page: 18
  year: 2017
  ident: B22
  article-title: T memory stem cells in health and disease
  publication-title: Nat Med
  doi: 10.1038/nm.4241
– volume: 10
  year: 2022
  ident: B72
  article-title: Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-003958
– volume: 3
  year: 2023
  ident: B57
  article-title: Targeting the biology of aging with mTOR inhibitors
  publication-title: Nat Aging
  doi: 10.1038/s43587-023-00416-y
– volume: 62
  start-page: 39
  year: 2018
  ident: B110
  article-title: PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2017.10.002
– volume: 537
  year: 2016
  ident: B108
  article-title: Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection
  publication-title: Nature
  doi: 10.1038/nature19317
– volume: 15
  year: 2024
  ident: B4
  article-title: A Ménage à trois: NLRC5, immunity, and metabolism
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2024.1426620
– volume: 495
  year: 2018
  ident: B43
  article-title: Short-term culture with IL-2 is beneficial for potent memory chimeric antigen receptor T cell production
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2017.12.041
– volume: 16
  start-page: 123
  year: 2024
  ident: B104
  article-title: Epigenetics and immunotherapy in colorectal cancer: progress and promise
  publication-title: Clin Epigenet
  doi: 10.1186/s13148-024-01740-9
– volume: 45
  year: 2016
  ident: B25
  article-title: T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.07.021
– volume: 6
  start-page: 237ra67
  year: 2014
  ident: B96
  article-title: Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3007974
– volume: 12
  year: 2011
  ident: B9
  article-title: T cell exhaustion
  publication-title: Nat Immunol
  doi: 10.1038/ni.2035
– volume: 71
  start-page: 47
  year: 2020
  ident: B105
  article-title: CD40 agonist antibodies in cancer immunotherapy
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-062518-045435
– volume: 363
  year: 2010
  ident: B1
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1003466
– volume: 16
  year: 2025
  ident: B38
  article-title: Targeting Th9 cells in autoimmune diseases: a narrative review
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2025.1615611
– volume: 19
  year: 2019
  ident: B71
  article-title: Metabolic interventions in the immune response to cancer
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-019-0140-9
– volume: 19
  year: 2019
  ident: B115
  article-title: Epigenetic therapy in immune-oncology
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0109-9
– volume: 9
  year: 2024
  ident: B113
  article-title: CD5 deletion enhances the antitumor activity of adoptive T cell therapies
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.adn6509
– volume: 14
  year: 2014
  ident: B24
  article-title: T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3740
– volume: 3
  year: 2018
  ident: B30
  article-title: Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.96976
– volume: 28
  start-page: 35
  year: 2016
  ident: B50
  article-title: Reprogramming away from the exhausted T cell state
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2015.10.007
– volume: 24
  year: 2022
  ident: B46
  article-title: An intercellular transfer of telomeres rescues T cells from senescence and promotes long-term immunological memory
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-022-00991-z
– volume: 26
  year: 2025
  ident: B92
  article-title: Differential roles of human CD4(+) and CD8(+) regulatory T cells in controlling self-reactive immune responses
  publication-title: Nat Immunol
  doi: 10.1038/s41590-024-02062-x
– volume: 217
  year: 2018
  ident: B47
  article-title: A Ca(2+)-stimulated exosome release pathway in cancer cells is regulated by Munc13-4
  publication-title: J Cell Biol
  doi: 10.1083/jcb.201710132
– volume: 26
  year: 2024
  ident: B28
  article-title: Toxicities from BRAF and MEK inhibitors: strategies to maximize therapeutic success
  publication-title: Curr Oncol Rep
  doi: 10.1007/s11912-024-01544-3
– volume: 39
  start-page: 928
  year: 2021
  ident: B15
  article-title: Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.04.004
– volume: 66
  year: 2014
  ident: B60
  article-title: Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.38261
– volume: 30
  year: 2024
  ident: B5
  article-title: Class II transactivator restricts viral replication, extending its effect to HBV
  publication-title: Clin Mol Hepatol
  doi: 10.3350/cmh.2024.0465
– volume: 19
  start-page: 116
  year: 2020
  ident: B90
  article-title: Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01234-1
– volume: 127
  start-page: 91
  year: 2016
  ident: B61
  article-title: Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells
  publication-title: Blood
  doi: 10.1182/blood-2015-06-649145
– volume: 203
  year: 2006
  ident: B98
  article-title: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
  publication-title: J Exp Med
  doi: 10.1084/jem.20061104
– volume: 558
  year: 2018
  ident: B112
  article-title: Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
  publication-title: Nature
  doi: 10.1038/s41586-018-0178-z
– volume: 121
  year: 2013
  ident: B39
  article-title: IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
  publication-title: Blood
  doi: 10.1182/blood-2012-05-431718
– volume: 24
  year: 2018
  ident: B93
  article-title: Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1231
– volume: 19
  start-page: 689
  year: 2017
  ident: B42
  article-title: Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2017.03.067
– volume: 26
  year: 2025
  ident: B14
  article-title: Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer
  publication-title: Nat Immunol
  doi: 10.1038/s41590-025-02134-6
– volume: 249
  start-page: 27
  year: 2012
  ident: B79
  article-title: Metabolic switching and fuel choice during T-cell differentiation and memory development
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2012.01150.x
– volume: 14
  start-page: 6858
  year: 2023
  ident: B21
  article-title: Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-42634-3
– volume: 348
  start-page: 74
  year: 2015
  ident: B13
  article-title: T cell exclusion, immune privilege, and the tumor microenvironment
  publication-title: Science
  doi: 10.1126/science.aaa6204
– volume: 35
  year: 2014
  ident: B49
  article-title: Reprogramming antitumor immunity
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2014.02.003
– volume: 70
  year: 2019
  ident: B99
  article-title: Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.10.040
– volume: 125
  year: 2015
  ident: B101
  article-title: Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
  publication-title: J Clin Invest
  doi: 10.1172/JCI80005
– volume: 10
  start-page: 109
  year: 2017
  ident: B68
  article-title: Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0478-z
– volume: 386
  year: 2024
  ident: B20
  article-title: Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy
  publication-title: Science
  doi: 10.1126/science.adl4492
– volume: 8
  year: 2018
  ident: B3
  article-title: Fundamental mechanisms of immune checkpoint blockade therapy
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0367
– volume: 22
  year: 2021
  ident: B6
  article-title: The MHC class II transactivator CIITA: not (Quite) the odd-one-out anymore among NLR proteins
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22031074
– volume: 50
  start-page: 195
  year: 2019
  ident: B31
  article-title: Intratumoral tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.12.021
– volume: 25
  year: 2005
  ident: B8
  article-title: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.25.21.9543-9553.2005
– volume: 10
  year: 2019
  ident: B41
  article-title: Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
  publication-title: Protein Cell
  doi: 10.1007/s13238-019-0643-y
– volume: 9
  year: 2021
  ident: B53
  article-title: Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001536
– volume: 12
  year: 2013
  ident: B51
  article-title: Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2012.11.002
– volume: 28
  year: 2015
  ident: B37
  article-title: Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.09.004
– volume: 583
  year: 2020
  ident: B59
  article-title: Senolytic CAR T cells reverse senescence-associated pathologies
  publication-title: Nature
  doi: 10.1038/s41586-020-2403-9
– volume: 26
  year: 2020
  ident: B103
  article-title: Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-0113
– volume: 22
  start-page: 2
  year: 2022
  ident: B86
  article-title: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-02407-8
– volume: 12
  start-page: 54
  year: 2024
  ident: B52
  article-title: CRISPR/Cas-based CAR-T cells: production and application
  publication-title: biomark Res
  doi: 10.1186/s40364-024-00602-z
– volume: 2
  year: 2022
  ident: B16
  article-title: Mavorixafor, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and inflammatory status of tumor microenvironment in patients with melanoma
  publication-title: Cancer Res Commun
  doi: 10.1158/2767-9764.CRC-22-0090
– volume: 169
  start-page: 132
  year: 2017
  ident: B58
  article-title: Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
  publication-title: Cell
  doi: 10.1016/j.cell.2017.02.031
– volume: 21
  year: 2015
  ident: B91
  article-title: Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-0830
– volume: 20
  year: 2014
  ident: B63
  article-title: Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2014.03.007
– volume: 13
  start-page: 10
  year: 2020
  ident: B17
  article-title: Myeloid-derived suppressor cells-new and exciting players in lung cancer
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-0843-1
– volume: 11
  start-page: 91
  year: 2018
  ident: B67
  article-title: T cell senescence and CAR-T cell exhaustion in hematological Malignancies
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0629-x
– volume: 36
  year: 2015
  ident: B10
  article-title: Overcoming T cell exhaustion in infection and cancer
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2015.02.008
– volume: 15
  start-page: 24
  year: 2022
  ident: B85
  article-title: Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01242-2
– volume: 576
  year: 2019
  ident: B83
  article-title: Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
  publication-title: Nature
  doi: 10.1038/s41586-019-1821-z
– volume: 11
  year: 2021
  ident: B94
  article-title: Myeloid-derived suppressor cells: A propitious road to clinic
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-21-0764
– volume: 13
  year: 2022
  ident: B100
  article-title: Immunotherapy of targeting MDSCs in tumor microenvironment
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.990463
– volume: 7
  year: 2019
  ident: B34
  article-title: Metabolic consequences of T-cell costimulation in anticancer immunity
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-19-0115
– volume: 23
  year: 2017
  ident: B66
  article-title: Cell-based therapy using umbilical cord blood for novel indications in regenerative therapy and immune modulation: an updated systematic scoping review of the literature
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2017.05.032
– volume: 123
  year: 2013
  ident: B74
  article-title: Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
  publication-title: J Clin Invest
  doi: 10.1172/JCI69589
– volume: 43
  year: 2025
  ident: B29
  article-title: Bioengineering lipid-based synthetic cells for therapeutic protein delivery
  publication-title: Trends Biotechnol
  doi: 10.1016/j.tibtech.2024.08.004
– volume: 6
  start-page: 268ra179
  year: 2014
  ident: B55
  article-title: mTOR inhibition improves immune function in the elderly
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3009892
– volume: 15
  year: 2022
  ident: B106
  article-title: Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development
  publication-title: Clin Transl Sci
  doi: 10.1111/cts.13387
– volume: 388
  year: 2023
  ident: B48
  article-title: Familial clonal hematopoiesis in a long telomere syndrome
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2300503
– volume: 12
  year: 2024
  ident: B26
  article-title: MR1 gene and protein expression are enhanced by inhibition of the extracellular signal-regulated kinase ERK
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-24-0110
– volume: 26
  year: 2006
  ident: B2
  article-title: The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas
  publication-title: Iowa Orthop J
– volume: 3
  year: 2018
  ident: B35
  article-title: Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.99048
– volume: 9
  start-page: 34
  year: 2020
  ident: B40
  article-title: Engineering better chimeric antigen receptor T cells
  publication-title: Exp Hematol Oncol
  doi: 10.1186/s40164-020-00190-2
– volume: 29
  year: 2016
  ident: B97
  article-title: CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.04.014
– volume: 23
  year: 2022
  ident: B7
  article-title: Joining forces for cancer treatment: from "TCR versus CAR" to "TCR and CAR
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms232314563
– volume: 537
  year: 2016
  ident: B23
  article-title: Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
  publication-title: Nature
  doi: 10.1038/nature19330
– volume: 17
  start-page: 46
  year: 2024
  ident: B56
  article-title: Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-024-01563-4
– volume: 58
  start-page: 616
  year: 2025
  ident: B19
  article-title: Collaboration between interleukin-7 and -15 enables adaptation of tissue-resident and circulating memory CD8(+) T cells to cytokine deficiency
  publication-title: Immunity
  doi: 10.1016/j.immuni.2025.02.009
SSID ssj0000493335
Score 2.3906944
SecondaryResourceType review_article
Snippet T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion,...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 1662145
SubjectTerms Animals
Cellular Senescence - immunology
Humans
Immunotherapy - methods
Immunotherapy, Adoptive - methods
Lymphocyte Activation
metabolic regulation
microenvironment optimization
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - therapy
T-cell enhancement
T-cell exhaustion and aging
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
T-Lymphocytes - transplantation
tumor immunotherapy
Tumor Microenvironment - immunology
Title Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression
URI https://www.ncbi.nlm.nih.gov/pubmed/41159033
https://www.proquest.com/docview/3266457063
https://doaj.org/article/52a5a61a596f4ea4b6d8606bee0a2e44
Volume 16
WOSCitedRecordID wos001600214200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PTxUxEJ4gwcSLEfz1VEhNvMnK7va3NyAQD_jiAc27Ne22FUxYCO89Ixf-dma2C8GD4eJlD5tm2_1m2vmmab8B-BANkljViUpjPKpE5rwyWatKxCB4G3USQxWFH0d6OjWzmf12r9QXnQkr8sAFuB3ZeulV46VVWSQvgooGSXdIqfYtfolW31rbe8nUr8J7Oeey3JLBLMzu5NOzsyXmg6381ChF-tx_RaJBsP_fLHOINofP4OlIE9luGd46rKR-Ax6XwpFXz2E2pYT15yAZTciyY0Y78Ix678c7VVefGR3PRI_C6MTSnxNS-MG222xO61tHU3qb-T6y-fJiPA7bv4DvhwfH-1-qsUZC1XGlFlXqahV5MNp0SK2UjcpmH6wMGLYNYpasbqOIDfKUUCeJs61ts0EAJFILDF78Jaz25316DSxk3jQhSc8FFymYkKOwweTgfQy21RP4eIuXuyhSGA5TCELXDeg6QteN6E5gjyC9a0ky1sMLNK4bjeseMu4E3t8axKHbE5K-T-fLuUPWqYTUSLAm8KpY6q4rgSzX1py_-R9DeAtP6LfKrss7WF1cLtMmrHW_F6fzyy14pGdma_A9fH69PrgB_VXdxg
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Next-generation+T+cell+immunotherapy%3A+overcoming+exhaustion%2C+senescence%2C+and+suppression&rft.jtitle=Frontiers+in+immunology&rft.au=Li%2C+Guangmei&rft.au=Li%2C+Dengju&rft.au=Zhu%2C+Xiaojian&rft.date=2025&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=16&rft_id=info:doi/10.3389%2Ffimmu.2025.1662145&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2025_1662145
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon